BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study. Aliment Pharmacol Ther 2022;56:713-22. [PMID: 35735794 DOI: 10.1111/apt.17107] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Yip TC, Lai JC, Liang LY, Hui VW, Wong VW, Wong GL. Risk of HCC in Patients with HBV, Role of Antiviral Treatment. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00588-y] [Reference Citation Analysis]
2 Wang ML, Chen EQ. Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B. Aliment Pharmacol Ther 2022;56:1090-1. [PMID: 35995741 DOI: 10.1111/apt.17122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ogawa E. Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues-treated patients with chronic hepatitis B - author's reply. Aliment Pharmacol Ther 2022;56:1092-3. [PMID: 35995743 DOI: 10.1111/apt.17173] [Reference Citation Analysis]
4 Sato K, Inoue J, Akahane T, Kobayashi T, Takai S, Nakamura T, Sato T, Kimura O, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Onuki M, Sawahashi S, Niitsuma H, Masamune A. Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir. Tohoku J Exp Med 2022;258:277-285. [DOI: 10.1620/tjem.2022.j084] [Reference Citation Analysis]